A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with nAMD

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2021 - November 30, 2022